Raydiant Oximetry, Inc. is revolutionizing fetal health monitoring with a groundbreaking invention that harnesses advanced light-based technology and machine learning to non-invasively determine fetal blood oxygen levels. This innovation addresses a critical gap in prenatal care, where current methods, such as fetal heart rate monitoring, often fail to accurately detect fetal distress, leading to unnecessary interventions like Cesarean sections. By combining simulations, real-world data, and artificial intelligence, Raydiant Oximetry has developed a system capable of predicting fetal oxygen saturation with unprecedented accuracy.

At the heart of this invention is a method that uses light applied to the abdomen of a pregnant mammal to collect signals from both the mother and the fetus. These signals are then analyzed using a trained machine learning model developed through a combination of simulated and real data. The model is trained using simulations of light transmission through tissue models that replicate the optical properties of maternal and fetal tissues, including factors such as skin color, melanin content, and blood oxygen levels. This simulated data is then refined with measured in vivo data, creating a robust and accurate predictive tool.

The system is capable of determining both fetal hemoglobin oxygen saturation and tissue oxygen saturation, providing critical insights into fetal health. It can also detect conditions such as fetal hypoxia or hypoxemia, alerting healthcare providers in real-time to potential risks. By isolating the fetal signal from composite data, the system ensures that the analysis is focused exclusively on the fetus, improving accuracy.

What distinguishes this invention is its ability to overcome the difficulties associated with obtaining sufficient in vivo data for training. by using simulations to generate a vast dataset of scenarios, Raydiant Oximetry has created a model that can be optimized with a minimal amount of real data, significantly reducing development time and costs. This approach not only accelerates the path to clinical application but also ensures the model’s adaptability to diverse populations and conditions.

This technology has the potential to transform prenatal care, providing clinicians with a reliable and non-invasive tool to monitor fetal well-being and make informed decisions during pregnancy and labor. By bridging the gap between simulation and real-world application, Raydiant Oximetry is paving the way for safer and more effective maternal and fetal healthcare.

Are you developing new technologies for an existing application? Did you know that your development work could fall under the French Research and Development (R&D) Tax Credit? Your project could qualify for incentives, even if the development is not successful (for example, you do not need to have a patent to qualify). To learn more about how to obtain significant tax benefits for your company, we invite you to contact a Swanson Reed R&D Specialist today or consult our free online eligibility test.

Who We Are:

Swanson Reed is one of the largest tax consulting firms specializing in R&D. We manage all aspects of Research and Development tax credit programs, from claim preparation to compliance in the event of an audit and dispute resolution.

Swanson Reed regularly organizes free webinars and provides credits for continuing professional education. For more information, please visit www.swansonreed.fr/webinar-gratuito or contact your trusted Swanson Reed representative.